TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05785949

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Use of standard tool kit to drill vertically from the periphery to the center with a hole spacing of 3\~4 mm with care to prevent penetrating adjacent holes. The hole depth should be 3\~5 mm and fat droplets or blood oozing is seen after loosening the tourniquet. However, no blood oozing is observed in some holes and in such case, the hole depth should be deepened to 5\~7 mm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture
Description: Use of standard tool kit to drill vertically from the periphery to the center with a hole spacing of 3\~4 mm with care to prevent penetrating adjacent holes. The hole depth should be 3\~5 mm and fat droplets or blood oozing is seen after loosening the tourniquet. However, no blood oozing is observed in some holes and in such case, the hole depth should be deepened to 5\~7 mm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chondro-Gide bilayer collagen membrane
Description: After the Microfracture, the porous layer of the bilayer collagen membrane faces the bone surface. The already trimmed, cut and wetted membrane is insert into the defect and fixed symmetrically with absorbable surgical suture with needle. Knots are put on the pinhole of collagen membrane to avoid tearing of surrounding cartilage or collagen membrane during knotting.
Study: NCT05830344

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Multi Radiance Medical® Super Pulsed Laser
Description: Placebo, without therapeutic dose.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Multi Radiance Medical® Super Pulsed Laser
Description: Active with a dose of 8.02 J per site.
Study: NCT05906524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD6001
Description: KD6001 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD6001
Description: KD6001 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously.
Study: NCT04935684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Patients randomized in the FMT group will received FMT within 4 weeks following neutrophils recovery after the allo-HSCT procedure. The stool transplant will be done by enema. The day before FMT, patient will undergo bowel cleansing by ingestion of two liters of polyethylene glycol solution. The day of FMT, a colon cleanse enema will be performed in the morning and FMT will be delivered around two hours after the cleanse enema. This colic preparation is essential to optimize the results of FMT.~The enema (50g of stools diluted in 250mL of NaCl 0.9%) will be performed by a qualified member of the study team (nurse) by using a rectal cannula (within 6 hours of thawing). The enema will have to be kept by the patient for as long as possible and at least 30 minutes.
Study: NCT05940051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib, Polatuzumab vedotin and Rituximab
Description: Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m2 ivgtt D1
Study: NCT04284059

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo, vitamin AD and vitamin D are identical in the appearance to guarantee blind. The patients need to administrate 3 capsules once a day for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin AD
Description: A vitamin AD capsule contains vitamin A 2000 IU and vitamin D 700 IU. The patients need to administrate 3 capsules once a day for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: A vitamin D capsule contains vitamin D 400 IU. The patients need to asministrate 6 capsules/time, once a day for 2 weeks, then change to 5 capsules/time, once a day for 6 weeks.
Study: NCT05114278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: Experimental group will receive intravenous iron infusion (Ferinject©: 15 mg/kg in NaCl solution IV) at randomization, 2weeks after randomization, 4weeks after randomization, and then every month for a total of one year. Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral iron
Description: All patients will receive an oral iron supplementation (100mg/day).
Study: NCT05234762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES-481
Description: Dose escalation during two Treatment Periods

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dosed at same dosing as ES-481
Study: NCT05042960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brightness
Description: Changing the colors or brightness on the device (computer screen) for one month

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brightness
Description: Changing the colors or brightness on the device (computer screen) for one month
Study: NCT05114278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral iron
Description: All patients will receive an oral iron supplementation (100mg/day).
Study: NCT05059964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit Training program
Description: The 4 weeks Circuit Training program, it will be of 3 times per week. Each CT workout includes 6 stations per circuit Training. Before the training period, all participants underwent an exercise familiarization session to ensure proper execution of technique.~The 6 stations will be included as 40 lb. carry for 100 ft., 3-min stair climb, 45 s plank pose, 20 lb. carry with a fast walk for 100 ft., right and left single leg stands for as long as balance was maintained, and a 15 lb. carry up and down 30 stairs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous aerobic exercise Group
Description: Continuous aerobic exercise Frequency 3 time per week Intensity 50% of Heart rate reserve Type continuous aerobic exercise Time 40 minutes
Study: NCT04815226

Intervention type: DEVICE
Group type: OTHER
Intervention: Peristeen Transanal Irrigation
Description: Using Peristeen Transanal Irrigation twice per week for 12 weeks
Study: NCT05729139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab-Rwlc
Description: 350 mg via IV infusion over 30 minutes every 3 weeks for up to two years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a
Description: Self-administered by the participant via subcutaneous injection in the abdomen or thigh weekly for up to one year. Participants will receive one of three doses:~Dose level 0: 45 mcg~Dose level 1: 90 mcg~Dose level 2: 135 mcg~Dose level 0 is considered the starting dose and sequential cohorts of three participants will be treated with escalated doses until the maximum tolerated dose is established.
Study: NCT06326658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bufei Yishen Prescription Granule
Description: The comparison group was given Bufei Yishen Prescription Granule.The course of treatment was the same as that of the experimental group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bufei Yishen Prescription Granule
Description: The comparison group was given Bufei Yishen Prescription Granule.The course of treatment was the same as that of the experimental group.
Study: NCT05238324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetic HMI-203
Description: HMI-203 delivered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetic HMI-203
Description: HMI-203 delivered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetic HMI-203
Description: HMI-203 delivered intravenously
Study: NCT04823858

Intervention type: PROCEDURE
Intervention: Lumbar Interbody Fusion
Description: The TLIF/PLIF system includes a TLIF/PLIF interbody cage and a pedicle screw system (4 screws with 2 rods). Any FDA cleared TLIF/PLIF interbody cage and pedicle screw system is acceptable for this study (with the exception of PEEK rods) as long as it is implanted per the package insert. No subjects implanted with an off-label use of a device are permitted for this study.
Study: NCT05057377

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard Overground Assessment
Description: The standard overground methods to assess three main components of walking are the 10 Meter Walk Test (meters/second, used to measure speed), 5x Sit-to-Stand (seconds, used to measure strength), and the 6-Minute Walk Test (meters, used to measure endurance).

Intervention type: DIAGNOSTIC_TEST
Intervention: Robotic Safety-Environment Assessment
Description: The methods for assessment of the three main components of walking in the robotic environment will be the maximum walking speed tolerated (meters/second, to measure speed), deadband resistance (kilograms, to measure strength), and the 6-minute walk test (meters, to measure endurance).
Study: NCT04946734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFO closure device
Description: Device PFO closure.

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin and clopidogrel
Description: Aspirin 100mg qd for 6 months and clopidogrel 75mg qd administered for 1month after device implanted.
Study: NCT06085768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VRE intervention
Description: Virtual reality exposure therapy is a new treatment technology developed in recent years. This technology combines virtual reality technology with traditional exposure therapy, and uses virtual reality technology to present the exposure scenes required for exposure therapy. Therefore, it can break through the limitations of time and space and more intuitively display some things that are difficult to simulate in the treatment room. Scenes do not require the client to undergo treatment through imaginary exposure, thereby increasing the immersion and reality of the treatment. Over the past two decades, numerous studies have explored and proven the effectiveness of virtual exposure therapy.
Study: NCT05504928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School nurse program
Description: School nurse program providing health care through assessment, intervention and follow-up of group A β-hemolytic streptococcal pharyngitis and facilitation of secondary antibiotic prophylaxis for children with latent rheumatic heart disease.
Study: NCT06320964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TARANG
Description: For newly married women, the intervention had one introductory rapport-building session, followed by 16 group sessions facilitated by trained female moderators over 5 months. The intervention aimed to empower participants by enhancing their understanding of fundamental topics such as menstruation, conception, and contraception, choice of a method among others. Sessions also covered topics to strengthen participants' sense of agency and their ability to make informed decisions regarding family planning and the timing of their first childbirth. Similarly, for husbands, a male moderator delivered sessions on four topics: Love, Relationships and Expectations; Conception and Health; Contraception Methods, and how to choose family planning methods. For MILs, a female moderator covered four sessions: Nutrition flag, Conception and Health, communication between family members, and the final session on relationships with daughter-in-law.
Study: NCT05539742

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coconut oil
Description: Coconut oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
Study: NCT06105359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dignity therapy
Description: Dignity therapy will be applied in the interview room that will be requested in the oncology clinic to protect the confidentiality of information.~The application is planned as five sessions and the sessions will last approximately 40 minutes. Two questions in the dignity therapy protocol will be discussed in each session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardize care
Description: Patients in this group will receive standard treatment and care in the clinic. No action will be taken other than standard care.
Study: NCT05539742

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Palm oil
Description: Palm oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
Study: NCT04984252

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-compassion comprising compassionate body scan-1, compassion body scan-2 and short noticing practice
Description: This intervention includes 3 short meditations that are identified as the active component in the previous study (ID: NCT04665167)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Self-compassion comprising self-compassion break, loving kindness meditation, and breathing exercise.
Description: This intervention includes 3 short meditations that are identified as the inactive component in the previous study (ID: NCT04665167)
Study: NCT04946734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel
Description: Aspirin 100mg qd for 6 months and clopidogrel 75mg qd administered for 1month after device implanted.

Intervention type: DRUG
Group type: OTHER
Intervention: Triptans
Description: If migraine recurred, Triptans would be administered during the acute phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptans
Description: If migraine recurred, Triptans would be administered during the acute phase.
Study: NCT06105359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardize care
Description: Patients in this group will receive standard treatment and care in the clinic. No action will be taken other than standard care.
Study: NCT00980304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT05135611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 channel Electrical Stimulation Device
Description: electrical stimulation at muscles which related with sleep apnea,. 4-channel NMES is the protocol that provides sequential electrical stimulation to Rt. suprahyoid m (channel 1), Lt.suprahyoid m (channel 2), bilateral thyrohyoid m (channel 3), and biltateral sternothyroid m (channel 4). At this time, channels 1 and 2 start to contract first and stimulate for 1200ms, and channel 3 starts stimulation 150ms after channels 1 and 2, and applies stimulation for 1050ms. Channel 4 starts stimulation 250ms after stimulation of channels 1 and 2 and stimulates it for 950 ms.
Study: NCT05262686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belimumab
Description: Belimumab was intravenously administrated at a dose of 10mg/kg once a month for at least 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab was intravenously administrated at a dose of 10mg/kg once a month for at least 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2
Description: Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
Study: NCT01958892

Intervention type: PROCEDURE
Intervention: TURP, TUERP

Intervention type: PROCEDURE
Intervention: TURP, TUERP
Study: NCT05992857

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy without retromesenteric omental flap
Description: Resection of the pancreatic head, duodenum, distal common bile duct and gallbladder followed by reconstruction using pancreaticojejunostomy, hepaticojejunostomy, and gastrojejunostomy performed on the first jejunal loop.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreaticoduodenectomy with retromesenteric omental flap
Description: All exposed peripancratic arteries should be covered with a retromesentric omental flap
Study: NCT04901416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DVX201
Description: Based upon the occurrence of DLT (does limiting toxicity), the MTD will be estimated as the highest dose at which the toxicity probability is the closest to the target probability (denoted pT=0.30) following up to 2 doses of DVX201. The corresponding dose allocation methodology is a modified toxicity interval design based upon (Ji et al., 2010; Ji et al., 2013).~All patients who have at least one dose initiated will be included in the safety analysis. Patients who are enrolled but never exposed to investigational product will be replaced for all analyses. Patients who get exposed to lymphodepleting chemotherapy will be followed and reported for outcomes overall, but for determination of safety and efficacy, only those subjects who have been exposed to the investigational agent will be included.
Study: NCT04546555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual chamber pacemaker
Description: Dual chamber pacemaker implantation with Bachmann's bundle lead and His bundle lead placement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual chamber pacemaker
Description: Dual chamber pacemaker implantation with Bachmann's bundle lead and His bundle lead placement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual chamber pacemaker
Description: Dual chamber pacemaker implantation with Bachmann's bundle lead and His bundle lead placement.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dual chamber pacemaker
Description: Dual chamber pacemaker implantation with Bachmann's bundle lead and His bundle lead placement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated Physiologic Pacing
Description: The lower rate limit will be programmed to an individualized heart rate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated Physiologic Pacing
Description: The lower rate limit will be programmed to an individualized heart rate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated Physiologic Pacing
Description: The lower rate limit will be programmed to an individualized heart rate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nocturnal Pacing
Description: In addition to adjustment of the lower rate limit to an individualized heart rate, nocturnal pacing a moderate HR elevation of 110bpm will be implemented between 8pm and 6am.
Study: NCT05914285

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5ml of inhaled normal saline
Description: After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5mg (2.5ml) of inhaled salbutamol and 2.5ml of inhaled normal saline
Description: After the initiation of OLV, mixture of salbutamol 2.5mg and normal saline 2.5ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
Study: NCT04984252

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Distraction group
Description: Participants will be asked to listen recording on irrelevant topic.
Study: NCT05613933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improved practices
Description: A package of tools including: antibiotic prophylaxis guidelines reminders, periodic reminders, the Infectious Endocarditis Prevention Card for patients at risk, practical information targeting both dentists and patients, etc...
Study: NCT06040281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensive individual support in nutrition and exercise
Description: Intensive care for nutrition and exercise adapted to the social context. Individualised exercise and nutrition recommendations.~three weeks of inpatient rehabilitation with an individual plan of treatment, which includes medical care, sports therapy, physiotherapy, ergotherapy, nutritional education and psychological care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)
Study: NCT04272333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motolimod
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Motolimod + Nivolumab
Description: Intratumoral microdose injection by the CIVO device.